China’s pharmaceutical manufacturing areas began recovering from coronavirus-related travel restrictions in mid-February, with production back up to half the normal rate, says US Pharmacopeia CEO Ron Piervincenzi.
The USP could detect that by reviewing Chinese sales of its physical reference standards.